Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.
It is well documented in the current literature that chronic heart failure is often associated with cachexia, defined as involuntary weight loss of 5 % in 12 month or less. Clinical studies unraveled that the presence of cachexia decreases significantly mean survival of the patient. At the molecular level mainly myofibrillar proteins are degraded, although a reduced protein synthesis may also contribute to the loss of muscle mass. Endocrine factors clearly regulate muscle mass and function by influencing the normally precisely controlled balance between protein breakdown and protein synthesis The aim of the present article is to review the knowledge in the field with respect to the role of endocrine factors for the regulation of cachexia in patients with CHF and deduce treatment perspectives.
Heart Center Leipzig, University Leipzig, Strümpellstrasse 39, 04289, Leipzig, Germany.
Norman
N
Mangner
Yae
Y
Matsuo
Gerhard
G
Schuler
Volker
V
Adams
D002100:Cachexia / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy*; D002908:Chronic Disease; D015897:Comorbidity; D004703:Endocrine System / Q000502:physiology*; D005081:Exercise Therapy; D006333:Heart Failure / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans